STOCK TITAN
  1. Home
  2. News
  3. SYNH

Syneos Health Inc - SYNH STOCK NEWS

Welcome to our dedicated news page for Syneos Health (Ticker: SYNH), a resource for investors and traders seeking the latest updates and insights on Syneos Health.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Syneos Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Syneos Health's position in the market.

News
Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting
Rhea-AI Summary
Mitsubishi Tanabe Pharma America, Inc. (MTPA) is set to present seven presentations at the AAN 2024 Annual Meeting, covering Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). The PD presentations include data from the Phase 3 BouNDless trial on investigational ND0612 efficacy and safety, onset data, and responder analysis. ALS data will focus on a preliminary analysis of RADICAVA ORS treatment demographics and real-world data from Canada. The company aims to share key insights and engage with the scientific community at the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone)
Rhea-AI Summary
Mitsubishi Tanabe Pharma America, Inc. receives Orphan Drug Exclusivity for RADICAVA ORS, an oral form of edaravone, for ALS treatment. The FDA acknowledges its significant contribution to patient care. RADICAVA ORS offers a self-administered, oral suspension route of administration, providing a clinically superior option to IV administration. The approval was based on a pivotal Phase 3 study showing a 33% slowdown in physical function loss compared to placebo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Syneos Health Closes Transaction with Private Investment Firms
Rhea-AI Summary
Syneos Health completes acquisition by private investment firms, becoming a privately held company. Stockholders receive $43.00 in cash per share. Transformation and technology investments expected to accelerate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Syneos Health Names Terttu Haring President, Clinical Sites & Patients
Rhea-AI Summary
Syneos Health appoints Terttu Haring as President, Clinical Sites & Patients to drive exceptional delivery, quality, and data integrity. Dr. Haring's experience will empower the team to execute data-driven solutions. The company aims to connect patients and sites worldwide using advanced data and technology. The appointment adds to a growing team of global therapeutic experts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
none
-
News
Syneos Health and Oracle to Expand Relationship to Accelerate Patient Recruitment & Advance Health Equity
Rhea-AI Summary
Syneos Health announces strategic collaboration with Oracle to improve patient recruitment for clinical studies
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
none
-
News
Syneos Health, Inc. and Star Parent, Inc. Announce Proposed $1.70 Billion Offering of Senior Secured Notes
Rhea-AI Summary
Star Parent, Inc. and Syneos Health announce $1.7B Senior Secured Notes offering to fund acquisition
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
News
Syneos Health Stockholders Approve Agreement with Private Investment Consortium
Rhea-AI Summary
Syneos Health, Inc. (SYNH) announced that stockholders approved the company's privatization through an acquisition by private investment firm affiliates. Stockholders will receive $43.00 in cash for each share of common stock. The transaction is expected to be completed in the second half of 2023, pending regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
none
-
News
Click Therapeutics Launches Additional Randomized Clinical Study in Migraine, Conducted in Partnership with Syneos Health
Rhea-AI Summary
Click Therapeutics, Inc. (Click) Announces Launch of ReMMiD-C Trial for Migraine Patients Receiving CGRP Inhibitor Therapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
partnership clinical trial
-
News
Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201
Rhea-AI Summary
FSD Pharma announces that an arbitration panel has found that Syneos Health failed to use commercially reasonable efforts in conducting its trial for FSD 201. Syneos Health had filed a claim against FSD Pharma, seeking damages of USD$3,915,388.69 for a failed Phase II FDA trial. The panel awarded Syneos Health $1,707,830.52 in damages plus interest. FSD Pharma countersued Syneos Health for breach of contract.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Syneos Health Appoints Hillary Bochniak as Chief Human Resources Officer
Rhea-AI Summary
Syneos Health appoints Hillary Bochniak as Chief Human Resources Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
management
Stock SYNH logo
Syneos Health Inc

Nasdaq:SYNH

SYNH Rankings

N/A Ranked by Market Cap
#2747 Ranked by Stock Gains
N/A Ranked by Dividends

SYNH Stock Data

4.46B
103.27M
0.49%
94.75%
6.52%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Morrisville

About SYNH

inc research/inventiv health has become syneos health, the only fully integrated end-to-end clinical and commercial solution organization. we are purpose-built for biopharmaceutical acceleration, creating better, smarter, faster ways to help clients navigate an increasingly complex marketplace. our new business addresses today’s market realities through clinical and commercial sharing expertise and data and insights to meet the needs of emerging and large global biopharmaceutical companies.